PharmaFocus Today – Page 20 – media

Three giants of IL-23, “making a big splash” in the ulcerative colitis market

Although global sales will exceed US$20 billion in 2023, the market ceiling for IL-23 inhibitors seems to be far from coming. The expansion of new indications remains the key to continued sales growth. Since 2023, Eli Lilly’s Mirikizumab, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya have been approved for UC (ulcerative colitis) indications and have quickly entered this market. According to a report released by Spherix Global Insights, IL-23 inhibitors have gained significant development momentum since their entry in 2023 and have occupied one-tenth of the UC market share in 2024. The above figures confirm the predictability of IL-23 inhibitors in the UC market. After all, in the highly competitive UC market, such growth is rare. But at the same time, as the number of competitors increases, different IL-23 inhibitor markets also need to worry about market share in the UC market. The competition has quietly begun. It is not ...
- Source: drugdu
- 81
- December 4, 2024
China’s bispecific antibodies compete in the multi-billion dollar race

The 66th American Society of Hematology (ASH) will be held in San Diego, USA from December 7 to 10, 2024. As one of the largest and most comprehensive international academic events in the field of hematology, it announces and publishes the latest hematology advances from all over the world every year. Multiple myeloma (MM), as the second most common hematological malignancy, has attracted the attention and layout of various pharmaceutical companies. At this year’s ASH conference, several Chinese bispecific antibodies/trispecific antibodies will be unveiled for MM indications. MM: The birthplace of the billion-dollar miracle drug Multiple myeloma is the second most common hematological malignancy after non-Hodgkin’s lymphoma. It is a malignant clonal plasma cell proliferative disease that causes extensive bone destruction, accompanied by osteolytic lesions, osteopenia and pathological fractures. It is called a blood disease that “eats” bones. According to the Chinese Multiple Myeloma Diagnosis and Treatment Guidelines (revised in ...
- Source: drugdu
- 78
- December 4, 2024
Received Approval Notification for Clinical Trials of Adsorbed Tetanus Vaccine

On December 2, Walvax Biologics announced that its joint application with its holding subsidiary, Yuxi Walvax Biotechnology Co., Ltd., for clinical trials of an adsorbed tetanus vaccine has recently received the “Drug Clinical Trial Approval Notification” issued by the National Medical Products Administration. After review, the adsorbed tetanus vaccine accepted on September 2, 2024, complies with the relevant requirements for drug registration and is approved to conduct clinical trials for the prevention of tetanus. https://finance.eastmoney.com/a/202412023256655359.html
- Source: drugdu
- 72
- December 4, 2024
Xiansheng Pharmaceutical’s Innovative Brain Cell Protection Drug Approved for Market

On December 1, Xiansheng Pharmaceutical’s innovative brain cell protection drug, Xianbixin sublingual tablets, was approved for market launch. Xianbixin is a dual-target brain cell protector that contains two active ingredients: Edaravone and R-(-)-Borneol. These ingredients work synergistically to enhance both antioxidant and anti-inflammatory effects, significantly reducing brain cell damage caused by acute ischemic stroke. In 2020, Xiansheng Pharmaceutical launched a Class 1 innovative drug, Xianbixin (in injectable form) in China, making it the only innovative drug approved in the stroke field globally in nearly a decade. https://finance.eastmoney.com/a/202412023256274687.html
- Source: drugdu
- 59
- December 4, 2024
There is one more loser in the AD field

There is one more loser in the Alzheimer’s disease field. On November 25, Cassava Sciences announced that the Phase III ReThink-ALZ study of Simufilam for the treatment of mild to moderate Alzheimer’s disease (AD) did not meet the pre-set dual primary endpoints, secondary endpoints, and exploratory biomarker endpoints. Affected by this news, Cassava Sciences’ stock price fell 84% that day. It seems that this may be expected. Cassava Sciences has been in great controversy because of controversies such as paper data falsification. But in any case, this still highlights the difficulty of treating Alzheimer’s disease. Simufilam is an oral small molecule drug targeting misconstructed filament protein A (FLNA). FLNA is a scaffold protein that normally exists in cells. The toxic form of amyloid beta, Aβ42, can induce changes in its structure, and the misconstructed FLNA can promote the activation of the Aβ42-α7 acetylcholine receptor signaling pathway and the Aβ42-Toll-like receptor ...
- Source: drugdu
- 78
- December 3, 2024
Allogeneic CAR-T heats up again

In the past week, the field of allogeneic CAR-T has heated up again due to the participation of Roche. On November 26, Roche announced that it would acquire the biotech company Poseida for up to $1.5 billion. Poseida’s R&D pipeline includes spot (allogeneic) CAR-T therapies in multiple therapeutic areas, covering hematological malignancies, solid tumors and autoimmune diseases. Due to a series of factors such as cycle and cost, the commercialization process of autologous CAR-T has been subject to certain restrictions, so the industry has never stopped exploring allogeneic CAR-T. The market has high hopes for allogeneic CAR-T. Of course, this is not smooth sailing, because due to a series of factors such as effect, it will take some time for allogeneic CAR-T to break through. Roche’s investment in Poseida this time is mainly based on the latter’s technology platform. Poseida’s non-viral platform is able to generate off-the-shelf CAR-T therapies ...
- Source: drugdu
- 72
- December 3, 2024
Changes in the Core of Medical Insurance Negotiations

After several years of practice, the thinking of medical insurance negotiations has completely changed. Drug prices still need to be controlled, and exchanging volume for price is the unshirkable responsibility of the Medical Insurance Bureau as a large buyer. However, the tone of the negotiations has changed. In the past few years, the Medical Insurance Bureau emphasized “soul bargaining”; but in this year’s medical insurance negotiations, the official tone of the Medical Insurance Bureau has become “two-way running.” “Going in both directions” means no longer just pursuing low prices, but negotiating with a reasonable price and stable expectations. For medical insurance, including more high-quality drugs through negotiations with pharmaceutical companies is to strive for the maximum benefits for insured persons on the basis of maintaining the stable operation of the fund; and for pharmaceutical companies, entering medical insurance can usually show significant benefits. By increasing sales, the commercialization process can ...
- Source: drugdu
- 84
- December 3, 2024
21 billion, the medical device giant officially announced a big move

Recently, Cardinal Health announced a major financial move, announcing the successful public offering of $2.9 billion in senior notes. The relevant details have been disclosed in the 8-K filing submitted to the U.S. Securities and Exchange Commission. On November 11, Cardinal announced that it would acquire GI Alliance and Diabetes Supply Group for $3.9 billion (approximately RMB 28.2 billion) to expand its business layout in the professional medical and home healthcare fields. Cardinal said that the funds raised from the note issuance will be used in part to provide financial support for its planned acquisition of a majority stake in GI Alliance Holdings, LLC and Advanced Diabetes Supply Group, covering related fees and expenses. The remaining funds will be used for general corporate purposes until they can be used for acquisitions. It is reported that the notes issued by Cardinal this time cover different maturities and interest rates, including $500 ...
- Source: drugdu
- 82
- December 3, 2024
AstraZeneca, who will replace Wang Lei?

Recently, AstraZeneca announced an important personnel change on its official website, appointing Bob Li, an Asian scientist at Memorial Sloan-Kettering Cancer Center (MSK) in the United States, as the new head of global medical affairs for oncology. He will report directly to David Fredrickson, head of AstraZeneca’s oncology business unit. Although Mr. Li is 42 years old and his position has not yet reached the company’s senior management, his Chinese identity and background have attracted widespread public attention. Mr. Li, an Australian-Chinese born in Shanghai, has served as a physician ambassador for China and the Asia-Pacific region at MSK, and is also a senior fellow in global public health at the China Analysis Center of the Asia Society Policy Institute. Mr. Li’s career shows that he has established cooperative relationships with many medical organizations in China, including a cooperative project between MSK and the China Thoracic Tumor Research Collaborative Group. ...
- Source: drugdu
- 82
- December 2, 2024
The first nasal “dry eye” treatment drug is approved for marketing

On November 27, Jixing Pharmaceutical announced that the National Medical Products Administration has approved the new drug application for its ophthalmic product, Varenicline tartrate nasal spray, to increase the tear secretion of patients with dry eyes. According to the data of “Chinese Dry Eye Expert Consensus (2020)”, the current incidence of dry eye in my country is about 21%-30%. Dry eye is closely related to excessive eye use, wearing contact lenses and other lifestyle habits. Common symptoms include dry eyes, foreign body sensation, burning sensation, itchy eyes, pain, red eyes, visual fatigue, blurred vision, and vision fluctuations. Natural tear deficiency and tear film instability are the core mechanisms of dry eye. Varenicline tartrate nasal spray is a highly selective acetylcholine receptor agonist that promotes natural tear secretion to stabilize the tear film by activating the trigeminal parasympathetic pathway. The approval data is based on the results of three key clinical ...
- Source: drugdu
- 81
- December 2, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.